Table 2. Summary of 1H-MRS Findings in Alzheimer's Disease

Study /
MR Protocol
/

Salient Findings

Miller et al (1993) / 1.5T STEAM Te = 30 / Parietal Cortex:
1.  NAA/Cr ¯ 5% in AD
2.  MI/Cr ­ 11% in AD
Occipital Cortex:
1.  NAA/Cr ¯ 11% in AD
2. MI/Cr ­ 22% in AD
Moats et al (1994) / 1.5T STEAM
Various Te / 1.  NAA ¯ 11% in AD
2.  MI ­ 50% in AD
3.  No Cho changes in AD
Meyerhoff et al (1994) / 2T CSI PRESS Te = 272 / 1.  NAA/Cr ¯ 12% in WM only
2.  Chol/Cr ­ 23% GM only
Follow up in posterior parietal area showed:
1.  30% ­ Chol/Cr in mesial GM
2.  27% ­ Chol/Cr in lateral WM
Mohankrishnan et al (1995) / Post-mortem in vitro / 1.  NAA depletion correlated with AD pathology
Shonk et al (1995) / 1.5T STEAM Te = 30 / 1.  AD, FTD, OD 10%¯ in NAA/Cr
2.  AD & FTD 15%­ in MI/Cr
3.  No Cho/Cr differences
4.  MRS discrimination of AD from:
§  Controls: Positive Predictive Value: 98%
§  Other Dementias: Positive Predictive Value: 74%; Negative Predictive Value: 80%
Parnetti et al (1996) / 1.5T STEAM Te = 20 / 1.  AD and AAMI NAA ¯ 12%
2.  AD MI ­ 22%; AAMI ns increase.
3.  No group Cho or Cr differences.
Parnetti et al (1997) / 1.5T STEAM
Te = 35 / 1.  AD ¯ NAA in GM (15%) and WM (8%)
2.  AD ­ MI 18% in grey matter only.
3.  NAA/MI 100% discrimination of AD
4.  Frontal WM MI & AD duration r= 0.70
Heun et al (1997) / 1.5T PRESS Te = 136 / 1.  AD 16% ¯ in NAA in WM
2.  No MI differences.
3.  NAA/Cho associated with Blessed Dementia rating (r=-0.69) and MMSE (r=0.82)
Satlin et al (1997) / 1.5T STEAM
Te = 272 / 1.  Six-month placebo control trial of xanomeline
2.  Repeat spectra found Cho/Cr decrease of about 20% compared to baseline in medication subjects only.
Doraiswamy et al (1998) / 1.5T CSI / 1.  Baseline MI/NAA strongly negatively correlated to MMSE score 12 months later (r=-0.70).
Rose et al (1999) / 2T VOSY
Te = 30 / 1.  Same day test-retest correlation of metabolite ratios was high.
2.  Longitudinal test-retest correlation of metabolite ratios was high for all ratios except Cho/Cr (r=0.50).
3.  AD patients has significantly ¯ NAA (15%) and ­ MI (18%).
4.  NAA/MI highly correlated with MMSE (r=0.8).
Pfefferbaum et al (1999) / 1.5T CSI / 1.  Gray matter NAA ¯ in AD after controlling for brain volume.
2.  Gray matter Cho ­ in AD.
3.  Higher Cho related to lower face-recognition scores (r= -0.7); higher Cr related to lower word recognition scores (r= -0.67).
Rai et al (1999) / 1.0T STEAM Te = 30 / 1.  Lower field strength MR scanners can also replicate abnormal MI/Cr elevation in AD
2.  Distribution of MI/Cr showed almost no overlap between AD and MID patients
Kantarci et al (2000) / 1.5T PRESS
Te= 135 & 30 / 1.  Three VOI: medial occipital, posterior cingulate (PC) and left superior temporal lobe (STL).
2.  AD ¯ NAA in STL and PC compared to MCI or Controls
3.  PC MI ­ in MCI and AD compared to controls


Jessen et al (2000) /
PRESS
Te=272 / 1.  AD medial temporal lobe (MTL) VOI showed ¯ NAA compared to controls and compared to within-individual primary motor cortex (PMC).
2.  No Cho changes in medial temporal lobe.
3.  NAA change (MTL/PMC) predicted MMSE and ADAScog scores (r=-0.54)
Haley et al (2000) / 1.5T STEAM
Te = 10 / 1.  No NAA or Cho changes in hippocampus of AD patients
2.  MI ­ in hippocampus 20%

Table 2. Summary of 1H-MRS findings in Alzheimer's disease.

All studies utilized the NINCDS-ADRDA criteria for AD diagnosis. Te = Echo time (msec). Groups: AD= Alzheimer's disease, AAMI= Age Associated Memory Impairment, MCI = Mild Cognitive Impairment, FTD= Fronto-temporal Dementia, MID = Multi Infarct Dementia, OD = Other Dementias, C= Controls, GM= Grey matter, WM= White Matter. ADAScog = Alzheimer Disease Assessment Scale cognitive subscale.